Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 3500
Single User License Price INR 240170
Corporate User License Price USD 10500
Corporate User License Price INR 720510
Site License Price USD 7000
Site License Price INR 480340
Request a Quote

Report Title

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Pipeline Review, H2 2018

Quote Request for License Type
License Type Price  
Single User License USD 3500
Site License USD 7000
Enterprise Wide License USD 10500
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Pipeline Review, H2 2018


Quote Request for License Type
License Type Price  
Single User License USD 3500
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Pipeline Review, H2 2018

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Pipeline Review, H2 2018



Executive Summary

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13)-Pipeline Review, H2 2018

Summary

According to the recently published report 'Protein Kinase C Epsilon Type-Pipeline Review, H2 2018'; Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) pipeline Target constitutes close to 7 molecules.

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13)-Protein kinase C (PKC) is an enzyme belonging to a family of serine- and threonine-specific protein kinases that is activated by calcium and the second messenger diacylglycerol. This kinase showed involvement in many different cellular functions, such as neuron channel activation, apoptosis, cardioprotection from ischemia, heat shock response, as well as insulin exocytosis.

The report 'Protein Kinase C Epsilon Type-Pipeline Review, H2 2018' outlays comprehensive information on the Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I and Preclinical stages are 1, 1 and 5 respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular, Genetic Disorders and Ophthalmology which include indications Alzheimer's Disease, Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C, Alcohol Addiction, Dry (Atrophic) Macular Degeneration, Fragile X Syndrome, Ischemic Stroke, Neurology, Rett Syndrome and Traumatic Brain Injury.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13)

- The report reviews Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics and enlists all their major and minor projects

- The report assesses Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13)-Overview

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13)-Companies Involved in Therapeutics Development

CHS Pharma Inc

Neurotrope Bioscience Inc

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13)-Drug Profiles

Bryostatin-1-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate Epsilon PKC for Ischemic Stroke-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate Epsilon PKC for Traumatic Brain Injury-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate PKC Epsilon for Neurology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate PRKCE for Alzheimer's Disease-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sulindac-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VMD-2202-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13)-Dormant Products

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13)-Discontinued Products

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13)-Product Development Milestones

Featured News & Press Releases

Sep 26, 2018: Neurotrope to Present Additional Phase 2 Data at the 11th Edition of Clinical Trials on Alzheimer's Disease (CTAD2018)

Jul 25, 2018: At AAIC 2018, Neurotrope presents additional clinical results showing cognitive improvement in phase 2 data assessing Bryostatin-1 in moderate-to-severe alzheimer's patients

Jul 16, 2018: Neurotrope Announces the Initiation of Enrollment of its Confirmatory Phase 2 Trial in Alzheimer's Disease

Jul 01, 2018: Neurotrope to Present Additional Phase 2 Data at the Alzheimer's Association International Conference (AAIC) 2018 Meeting

May 07, 2018: Neurotrope In Consultation With Leading Neuroscientists, Completes the Study Design for its Confirmatory Phase 2 Trial in Advanced Alzheimers Patients

Jan 05, 2018: Neurotropes Bryostatin Improves Cognition in Patients with Advanced Alzheimers Disease Based on Further Analysis of Phase 2 Clinical Trial Data

Dec 19, 2017: Neurotrope to Present Additional Findings from Bryostatin Phase 2 Trial in Advanced Alzheimer's Disease

Jul 19, 2017: Neurotrope Presents Phase 2 Data Assessing Bryostatin-1 in Moderate-to-Severe Alzheimer's Patients at AAIC 2017

Jun 29, 2017: Neurotrope to Present Bryostatin Phase 2 Data in an Oral Presentation at AAIC 2017 Meeting

May 01, 2017: NEUROTROPE Announces Positive Top-Line Results From Phase 2 Study of Bryostatin-1 for Moderate to Severe Alzheimer's Disease

Apr 28, 2017: Neurotrope Bioscience to Release Results From Phase 2 Clinical Trial in Moderate to Severe Alzheimer's Disease on May 1, 2017

Feb 28, 2017: Neurotrope Bioscience Concludes Patient Dosing and Monitoring in its 148 Patient Phase 2 Clinical Trial of Moderate to Severe Alzheimer's Dementia

Nov 22, 2016: Neurotrope Completes Enrollment in its Randomized, Double-Blinded, Placebo-Controlled Phase 2 Clinical Trial of Bryostatin in Patients With Moderate to Severe Alzheimers Disease

Aug 15, 2016: Neurotrope Submits an Amended Protocol to the U.S. Food and Drug Administration for its Phase 2b Clinical Trial of its Lead

Jun 21, 2016: Bryostatin, a PKC epsilon Activator, Generates New Synapses Through Accumulation of the Synaptic Anchoring Protein PSD-95 at Neuronal Membranes

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

List of Tables

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Indication, H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pipeline by CHS Pharma Inc, H2 2018

Pipeline by Neurotrope Bioscience Inc, H2 2018

Dormant Projects, H2 2018

Discontinued Products, H2 2018

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

CHS Pharma Inc

Neurotrope Bioscience Inc

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) Therapeutic Products under Development, Key Players in Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) Therapeutics, Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) Pipeline Overview, Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) Pipeline, Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) Pipeline Assessment


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand

person